News
BMS, AbbVie get FDA OK for new myeloma regimen
Bristol-Myers Squibb and AbbVie have picked up another FDA approval for their multiple myeloma drug Empliciti that they hope will help drive uptake of the drug.
Sunday 24 November 2024
